

2016 UK Emerging Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Instrument and Reagent Suppliers

https://marketpublishers.com/r/218E9F959A4EN.html

Date: October 2015

Pages: 575

Price: US\$ 5,440.00 (Single User License)

ID: 218E9F959A4EN

Abstracts

Highlights

Comprehensive 575-page analysis of the UK tumor marker testing market.

Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e. g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Five-year test volume and sales forecasts over for 40 tumor marker performed in UK hospitals, commercial laboratories and physician offices.

Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.



Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 575 pages and 85 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

- 1. MARKET OVERVIEW
- 2. WORLDWIDE MARKET STRUCTURE
- 3. WORLDWIDE MARKET SIZE AND GROWTH

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology



- 1. BREAST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEMIA
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SKIN CANCER
- 10. UTERINE CANCER
- 11. OVARIAN CANCER
- 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. INTRODUCTION
 - 2. TUMOR MARKER CLASSIFICATION
 - 3. ACTH
 - 4. ALPHA-FETOPROTEIN (AFP)
 - 5. BETA-2 MICROGLOBULIN
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. CALCITONIN
 - 10. CARCINOEMBRIONIC ANTIGEN (CEA)
 - 11. ESTROGEN AND PROGESTERONE RECEPTORS
 - 12. FERRITIN
 - 13. GASTRIN
 - 14. HUMAN CHORIONIC GONADOTROPIN (HCG)
 - 15. INSULIN
 - 16. NSE
 - 17. OCCULT BLOOD
 - 18. PAP SMEAR/HPV
 - 19. PROSTATIC ACID PHOSPHATASE (PAP)
 - 20. PROSTATE-SPECIFIC ANTIGEN (PSA)
 - 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
 - 22. T AND B LYMPHOCYTES
 - 23. TDT
 - 24. THYROGLOBULIN
 - 25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
 - 26. BIOCHEMICAL TUMOR MARKERS



27. ONCOGENES

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

28. POLYPEPTIDE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)



Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING TUMOR MARKERS

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15



Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

Intermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

Vimentin

KA

Kinases

KP16D3

LAI

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opiod Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative Index, Ki-67



1		
ı	Ρ	X

RB Inactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SLX

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG

TPS

Troponin

Tubulin

VCAM

VEGF

Villen

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. MONOCLONAL AND POLYCLONAL ANTIBODIES
 - 2. IMMUNOASSAYS
 - 3. MOLECULAR DIAGNOSTICS
 - 4. CHROMOSOME ANALYSIS
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. ARTIFICIAL INTELLIGENCE
 - 6. FLOW CYTOMETRY
 - 7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
 - 8. BIOSENSORS
 - 9. COMPETING/COMPLEMENTING TECHNOLOGIES
- E. Personal Testing



VIII. UK CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- **B.** Business Environment
- C. Market Structure
- D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

IX. COMPETITIVE PROFILES

Abbott

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/Vermillion

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Epigenomics

Enterix

Enzo Biochem

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences



Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Thermo

Veridex

Wako Pure Chemicals

Wallac/PE

Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS



List Of Tables

LIST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HPV Tests

Major Companies Developing or Marketing PAP Tests

Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests

Biochemical Markers Potential Applications In Cancer Diagnosis

Oncogenes Potential Applications In Cancer Diagnosis

Major Companies Developing or Marketing Oncogene Tests

Growth Factors Potential Applications In Cancer Diagnosis

Colony Stimulating Factors Potential Applications in Cancer Diagnosis

Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential Applications in Cancer Diagnosis

Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast by Market Segment

U.K., Estimated Cancer Death Rates Per 100,000 Population

U.K., Laboratories Performing Tumor Marker Tests by Market Segment

U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume



- U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
- U.K., All Market Segments Major Tumor Marker Test Volume Forecast
- U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
- U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
- U.K., Total Tumor Marker Sales Forecast by Market Segment
- U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
- U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Colon-Specific Antigen Test Volume And Diagnostics Sales by Market Segment
- U.K., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment



- U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
- U.K., Total Tumor Marker Sales and Market Shares Forecast
- U.K., CEA Testing Market Diagnostics Sales by Major Supplier
- U.K., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2016 UK Emerging Tumor Marker Testing Market: Emerging Opportunities and Growth

Strategies for Instrument and Reagent Suppliers

Product link: https://marketpublishers.com/r/218E9F959A4EN.html

Price: US\$ 5,440.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/218E9F959A4EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



